The new facility will produce biologic drugs and Keytruda, becoming Merck’s first in-house US site to make the blockbuster cancer treatment, the company said.

Summer begins early in Hollywood, on the first weekend in May and that kick-off can make or break that pivotal 123 day ...

Key Takeaways Regeneron Pharmaceuticals stock was among the biggest S&P 500 and Nasdaq decliners Tuesday after the biotech ...

Jammu: The Jammu and Kashmir State Investigation Agency (SIA) has achieved a breakthrough in its probe into a major drug trafficking case involving the recovery of 33 kg of heroin, with the arrest of ...

In a research report published in Psychedelics, Emory University investigators have uncovered the complex motivations driving ...

Novartis has a lot cooking with new drug launches, and the company is not letting potential U.S. tariffs on pharmaceuticals ...

Attorney General Pam Bondi traveled to a Drug Enforcement Administration lab to meet with chemists who are tasked with ...

Merck, the New Jersey-based drug giant, is spending $1 billion on a new Delaware factory to bring production of its best-selling cancer drug Keytruda to the U.S. and speed future drugs to market.

DC isn’t the only place where regulatory burden-boosting policy proposals are garnering bipartisan support. The same ...

Investing.com -- AstraZeneca (LON: AZN ) (ST: AZN) shares fell more than 3% Tuesday after the drugmaker missed first-quarter revenue expectations, with underperformance in key cancer and respiratory ...

We do not see JD Health to be in any financial distress. The balance sheet has CNY 200 million of debt compared with CNY 40 billion of cash and equivalents and almost no debt as of Dec. 31, 2024. The ...

Medpace has historically maintained a conservative balance sheet. At year-end 2024, cash and cash equivalents totaled $669 million. Medpace generated nearly $191 million in cash flow from operating ...